PureTech Health plc (PRTC)

NASDAQ: PRTC · Real-Time Price · USD
20.83
+0.13 (0.63%)
Nov 1, 2024, 3:00 PM EST - Market closed
0.63%
Market Cap 496.24M
Revenue (ttm) 468,000
Net Income (ttm) -82.47M
Shares Out 239.42M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,097
Open 20.95
Previous Close 20.70
Day's Range 20.44 - 20.95
52-Week Range 17.08 - 34.00
Beta 1.02
Analysts Buy
Price Target 45.00 (+116.04%)
Earnings Date Aug 28, 2024

About PRTC

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 90
Stock Exchange NASDAQ
Ticker Symbol PRTC
Full Company Profile

Financial Performance

In 2023, PureTech Health's revenue was $3.33 million, a decrease of -78.68% compared to the previous year's $15.62 million. Losses were -$65.70 million, 30.5% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PRTC stock is "Buy" and the 12-month stock price forecast is $45.0.

Price Target
$45.0
(116.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PureTech to Present at CHEST 2024 Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech to Present at CHEST 2024 Annual Meeting.

4 weeks ago - Business Wire

PureTech Health plc (PRTC) Q2 2024 Earnings Call Transcript

PureTech Health plc (NASDAQ:PRTC) Q2 2024 Earnings Conference Call August 28, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head of Communications Bharatt Chowrira - CEO Eric Elenko - Co...

2 months ago - Seeking Alpha

PureTech Health plc – Half-Year Report

BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.

2 months ago - Business Wire

PureTech Health: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.

2 months ago - Business Wire

PureTech Health: Results of the Tender Offer

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of the Tender Offer.

4 months ago - Business Wire

PureTech Announces Change of Board Role

BOSTON--(BUSINESS WIRE)--Raju Kucherlapati, PhD, has been appointed Chair of the PureTech Board of Directors.

4 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team.

4 months ago - Business Wire

PureTech Health: Results of Annual General Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of AGM.

5 months ago - Business Wire

PureTech Health: Result of General Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health: Result of General Meeting.

5 months ago - Business Wire

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.

Other symbols: AKLI
5 months ago - Business Wire

PureTech to Present at the Jefferies Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.

5 months ago - Business Wire

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study of VE303.

5 months ago - Business Wire

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

BOSTON--(BUSINESS WIRE)--PureTech Health: Launch of Proposed $100 million Tender Offer at 250 pence per Ordinary Share.

6 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting.

6 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments.

6 months ago - Business Wire

PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript

PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Allison Mead Talbot - Head, Communications Bharatt Chowrira - Chief Executive Officer...

6 months ago - Seeking Alpha

PureTech Announces Annual Results for Year Ended December 31, 2023

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2023.

6 months ago - Business Wire

PureTech Health: Notice of Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.

7 months ago - Business Wire

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

BOSTON--(BUSINESS WIRE)--PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis.

7 months ago - Business Wire

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers.

7 months ago - Business Wire

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

BOSTON--(BUSINESS WIRE)--PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions.

7 months ago - Business Wire

PureTech Health: Repeat What Works

PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's le...

8 months ago - Seeking Alpha

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded...

Other symbols: BMY
8 months ago - Business Wire

PureTech to Present at Two Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastat...

8 months ago - Business Wire

PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastat...

Other symbols: AKLI
9 months ago - Business Wire